Can-Fite BioPharma Ltd. (CANF) Bundle
A Brief History of Can-Fite BioPharma Ltd. (CANF)
Founding and Early Years
Founding and Early Years
Can-Fite BioPharma Ltd., established in 2000, focuses on the development of innovative therapies for the treatment of cancer, inflammation, and liver diseases. The company is headquartered in Petah Tikva, Israel. It was founded by Dr. Pnina Fishman, who has been pivotal in its strategic direction and research focus.
Key Developments and Products
Can-Fite's lead drug candidates include CF101 (namodenoson) and CF102 (toward treatment of hepatocellular carcinoma). Over the years, the company has made significant advances:
- 2013: Initiated a Phase II clinical trial for CF101 in patients with psoriasis.
- 2016: Announced positive results from a Phase II trial for CF101 in rheumatoid arthritis.
- 2019: Initiated a Phase III trial for CF101 in hepatocellular carcinoma.
- 2021: Completed a Phase II study showing promising results for CF102 in patients with liver cancer.
Financial Transactions and Stock Performance
Can-Fite went public on the Tel Aviv Stock Exchange in 2013, trading under the ticker CANF. The following financial highlights are noted:
| Year | Revenue (in USD) | Net Loss (in USD) | Stock Price (Year-End) | Market Capitalization (in USD) |
|---|---|---|---|---|
| 2018 | 1,176,000 | (5,883,000) | 1.20 | 15,000,000 |
| 2019 | 2,000,000 | (6,500,000) | 0.85 | 10,000,000 |
| 2020 | 1,500,000 | (8,049,000) | 0.45 | 7,500,000 |
| 2021 | 3,200,000 | (7,200,000) | 0.55 | 10,500,000 |
| 2022 | 2,800,000 | (6,850,000) | 0.40 | 9,000,000 |
| 2023 | 4,500,000 (Projected) | (5,500,000) (Projected) | 0.75 (Projected) | 12,000,000 (Projected) |
Clinical Trials and Regulatory Approvals
Can-Fite has undertaken numerous clinical trials to validate its product offerings:
- CF101: Multiple trials focusing on psoriatic arthritis and liver cancer.
- CF102: Trial results for hepatocellular carcinoma patients indicated potential for improved outcomes.
- Collaboration with the FDA for an Investigational New Drug (IND) application for CF101.
Strategic Partnerships
Over the years, Can-Fite has formed strategic partnerships to enhance its research and development capabilities:
- Collaboration with Helsinki University for clinical trials on liver diseases.
- Partnership with Roche for biomarker research.
- Agreements with various institutions for further developing CF101 and CF102.
Recent Developments and Future Outlook
As of October 2023, Can-Fite is in advanced stages of clinical trials and is actively seeking additional funding to support research initiatives aimed at expanding its portfolio. The company has a focus on regulatory approvals that will allow it to market CF101 and CF102 globally.
A Who Owns Can-Fite BioPharma Ltd. (CANF)
Current Ownership Structure
As of the latest financial filings, the ownership structure of Can-Fite BioPharma Ltd. (CANF) is distributed among various institutional and individual investors. The following table illustrates the major shareholders along with their respective ownership percentages:
| Shareholder | Ownership Percentage | Number of Shares Held |
|---|---|---|
| Discount Investment Corporation Ltd. | 17.0% | 6,200,000 |
| BlackRock Inc. | 6.5% | 2,350,000 |
| The Vanguard Group, Inc. | 5.2% | 1,900,000 |
| Other Institutional Investors | 25.5% | 9,300,000 |
| Individual Investors | 45.8% | 16,600,000 |
Top Institutional Investors
The following entities are among the top institutional investors holding shares in Can-Fite BioPharma Ltd.:
| Institution | Number of Shares | Investment Value (USD) |
|---|---|---|
| Discount Investment Corporation Ltd. | 6,200,000 | $17,500,000 |
| BlackRock Inc. | 2,350,000 | $6,500,000 |
| The Vanguard Group, Inc. | 1,900,000 | $5,200,000 |
| State Street Corporation | 1,500,000 | $4,000,000 |
| Pioneer Investments | 1,000,000 | $2,800,000 |
Recent Changes in Ownership
Over the past year, there have been significant changes in the ownership of the company:
- Discount Investment Corporation increased its stake by 5%.
- BlackRock reduced its holdings from 7% to 6.5%.
- Other institutional investors have collectively increased their shares by 2%.
- Individual investors have maintained a stable holding ratio.
Market Capitalization and Stock Performance
The market capitalization of Can-Fite BioPharma Ltd. as of the latest trading session stands at approximately $103 million. The stock has experienced volatility, with the following pertinent figures:
| Date | Stock Price (USD) | Market Capitalization (USD) |
|---|---|---|
| October 2, 2023 | $2.85 | $103 million |
| September 1, 2023 | $3.10 | $112 million |
| August 1, 2023 | $3.50 | $126 million |
| July 1, 2023 | $4.00 | $140 million |
| June 1, 2023 | $4.20 | $145 million |
Summary of Financial Health
According to the most recent financial reports, Can-Fite BioPharma Ltd. has reported the following key financial metrics:
| Financial Metric | Amount (USD) |
|---|---|
| Total Assets | $45 million |
| Total Liabilities | $12 million |
| Net Income (Last Fiscal Year) | -$5 million |
| Cash Reserves | $10 million |
| Revenue (Last Fiscal Year) | $8 million |
Potential Future Ownership Changes
With ongoing clinical trials and potential new partnerships, the ownership landscape of Can-Fite BioPharma Ltd. may shift significantly. Stakeholder interest remains high, and regulatory developments could lead to:
- Increased investment from venture capital firms.
- Potential acquisition proposals from larger pharmaceutical companies.
- Changes in institutional investment strategies based on performance metrics.
Can-Fite BioPharma Ltd. (CANF) Mission Statement
Overview
Can-Fite BioPharma Ltd. is a biopharmaceutical company that aims to develop innovative therapies for the treatment of cancer and inflammatory diseases. The mission statement of Can-Fite highlights its commitment to enhancing patient quality of life through the development of safe and effective drug therapies.
Core Values
- Innovation: Focused on cutting-edge research and development.
- Integrity: Upholding high ethical standards in all operations.
- Collaboration: Working with global partners to advance healthcare solutions.
- Patient-Centric Approach: Prioritizing the needs and well-being of patients.
Strategic Goals
- Drug Development: Advance the clinical development of lead candidates including Namodenoson and Piclidenoson.
- Market Expansion: Increase the availability of treatments in diverse geographic markets.
- Regulatory Approval: Obtain necessary approvals to commercialize therapeutic products.
- Partnership Development: Establish strategic alliances to enhance research capabilities and market reach.
Current Pipeline
| Drug Candidate | Indication | Phase of Development | Projected Milestone |
|---|---|---|---|
| Namodenoson | Hepatocellular Carcinoma | Phase III | Expected to report topline results in Q4 2023 |
| Piclidenoson | Psoriasis | Phase II | Expected to complete enrollment by Q2 2024 |
| CF101 | Autoimmune Diseases | Phase II | Targeting initiation of new trials by 2024 |
Financial Performance
As of 2023, Can-Fite BioPharma reported the following financial figures:
| Financial Metric | Amount (USD) |
|---|---|
| Revenue (2022) | 1.2 million |
| Net Loss (2022) | (8.5 million) |
| Total Assets | 15.0 million |
| Cash Position | 10.0 million |
R&D Investments
Can-Fite invests significantly in research and development to support its mission. In 2022, total R&D expenses were:
| Year | R&D Expenses (USD) |
|---|---|
| 2021 | 5.0 million |
| 2022 | 6.5 million |
| 2023 (Estimated) | 7.0 million |
Future Aspirations
Can-Fite aims to leverage its pipeline and partnerships to create value for stakeholders. The company is focused on:
- Enhancing Patient Access: Ensuring treatments are available to those in need.
- Expanding Research Collaborations: Partnering with academic and industry leaders.
- Innovating Therapies: Developing next-generation therapies targeting unmet medical needs.
How Can-Fite BioPharma Ltd. (CANF) Works
Company Overview
Company Overview
Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company that specializes in developing innovative therapies for cancer and inflammatory diseases. The company's primary focus is on its lead drug candidates, which target specific pathways in varying conditions.
Key Drug Candidates
- Namodenoson (CF101): A drug under investigation for the treatment of liver cancer, psoriasis, and other inflammatory diseases.
- CF102: This drug is aimed at treating hepatocellular carcinoma and is in the advanced stages of clinical trials.
Clinical Trials
- Namodenoson (CF101): A drug under investigation for the treatment of liver cancer, psoriasis, and other inflammatory diseases.
- CF102: This drug is aimed at treating hepatocellular carcinoma and is in the advanced stages of clinical trials.
Clinical Trials
Can-Fite is currently conducting numerous clinical trials to evaluate the efficacy and safety of its drug candidates. As of 2023, the number of ongoing clinical trials includes:
| Trial Name | Indication | Phase | Status | Estimated Enrollment |
|---|---|---|---|---|
| NCT03714780 | Liver Cancer | Phase 2 | Recruiting | 120 |
| NCT03872554 | Psoriasis | Phase 2 | Completed | 90 |
| NCT04015011 | Severe COVID-19 | Phase 2 | Ongoing | 150 |
Financial Performance
As of the latest quarterly report in Q3 2023, Can-Fite's financial performance includes:
| Metric | Q3 2023 | Q2 2023 | Change (%) |
|---|---|---|---|
| Revenue | $1.2 million | $1.1 million | +9.1% |
| Net Loss | ($3.5 million) | ($3.2 million) | +9.4% |
| Cash Reserves | $10.0 million | $12.0 million | -16.7% |
Market Strategy
Can-Fite focuses on strategic collaborations and partnerships to facilitate the development and commercialization of its drug candidates. Recent collaborations include:
- Collaboration with the University of Pittsburgh: Joint research on the applications of Namodenoson.
- Partnership with Eurofarma: Distribution agreement for the Latin American market.
Stock Performance
As of October 2023, Can-Fite’s stock (NASDAQ: CANF) shows the following performance metrics:
| Date | Closing Price | Market Capitalization | Trading Volume |
|---|---|---|---|
| October 27, 2023 | $1.50 | $47.8 million | 150,000 |
| October 20, 2023 | $1.40 | $45.5 million | 200,000 |
Regulatory Affairs
Can-Fite is actively engaged with regulatory agencies, including the U.S. FDA and EMA in Europe, to ensure compliance and facilitate the approval process for its drug candidates.
Conclusion
Can-Fite BioPharma Ltd. continues to push forward with its drug development pipeline while focusing on financial stability and strategic partnerships.
How Can-Fite BioPharma Ltd. (CANF) Makes Money
Revenue Streams
Can-Fite BioPharma Ltd. generates revenue primarily through the following streams:
- Clinical trial funding
- Licensing agreements
- Sales of proprietary drugs
- Grants and collaborations
Clinical Trial Funding
Can-Fite receives funding for various clinical trials from government agencies and private investors. For instance, in 2022, the company reported over $5 million in funding for its Phase 2 clinical trials, focusing on cancer and inflammatory diseases.
Licensing Agreements
Can-Fite has entered into multiple licensing agreements with pharmaceutical companies. The following tables outline some key licensing agreements and their associated financial terms:
| Partner Company | License Fee | Milestone Payments | Royalty Rate |
|---|---|---|---|
| Alzheimer's Therapeutics GmbH | $2 million | $1 million at IND approval | 10% |
| Chugai Pharmaceutical Co., Ltd. | $3 million | $2 million at Phase 3 commencement | 12% |
| PTC Therapeutics | $1.5 million | $1 million upon market approval | 8% |
Sales of Proprietary Drugs
Can-Fite markets proprietary drugs such as Namodenoson and CF101. In 2022, Namodenoson generated approximately $1.2 million in sales, while CF101 brought in around $800,000.
Grants and Collaborations
The company has successfully secured grants for research and development. In 2022, Can-Fite received a grant of $1 million from the Israel Innovation Authority for its development projects. Additionally, collaborative efforts have yielded approximately $500,000 in funding from academic institutions.
Expenses and Financial Management
To maintain profitability, Can-Fite manages its expenses effectively. In 2022, the total operating expenses amounted to $8 million, primarily due to R&D costs which represented around 70% of the total expenses.
Market Capitalization
As of October 2023, the company's market capitalization is approximately $35 million, showcasing its position in the biotech industry.
Stock Performance
Investors track Can-Fite’s stock performance closely. The stock price was valued at approximately $1.50 per share in October 2023, fluctuating based on clinical trial outcomes and market conditions.
Future Projections
Analysts project that with successful drug commercialization, Can-Fite could see revenue increase to around $10 million by 2025, depending on the outcomes of ongoing clinical trials and licensing negotiations.
Can-Fite BioPharma Ltd. (CANF) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support